Last week, the U.S. Food and Drug Administration (“FDA”) rung in the new year with a flurry of device-related activity, updating two final guidance documents and withdrawing a guidance published back in 2017. The two final guidance documents released on January 6, 2026 pertain to (1) General Wellness Devices and (2) Clinical Decision Support Software, and supersede previous versions of those guidance documents.[1] Then on January 7, 2026, FDA withdrew its guidance entitled “Software as a Medical Device (SAMD): Clinical Evaluation.”[2]
Latest Post
More Posts
FDA Continues Crack Down on DTC Advertising: Untitled Letter Highlights Pitfalls in Schizophrenia Drug Promotion
Texas Sues Johnson & Johnson and Kenvue Over Tylenol: Scientific Evidence, Regulatory Shifts, and the Future of OTC Drug Labeling
FDA’s Wave of Untitled Letters Signals Stricter Scrutiny for DTC Pharma Ads
FDA Unleashes Wave of Enforcement: The Industry Faces a Crackdown on Drug Advertising
FDA Ratchets Enforcement on Social Media Promotion in New Warning Letter
Onshoring Pharma Ops: Reading Recent EO and Policy Tea Leaves
Reminder: FDA Does, In Fact, Review DOF
Finally, FDA’s Final Word on Unapproved Use Communications
FDA Dumps Trio of Device-Related Guidances Prior to Administration Change
Subscribe: Subscribe via RSS